Merck
-
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Warmest congratulations to Merck and Orion, and to prostate cancer patients!
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
-
Is it too early for Akeso and Summit to celebrate? Merck executive comments on the explosive news that Keytruda has been successfully challenged
Just our two cents. All comments, including criticisms, are warmly welcome. Thank you all very much!
-
After ten years, Merck returns to the field of ophthalmology with a $3 billion investment!
Congratulations to Merck and EyeBio!